GSK plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr Charles Bancroft |
|||
b) |
Position/status |
Senior Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044
|
|||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2022 to 30 September 2022.
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$31.02 |
2,673.774 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2022-09-23 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Dr Anne Beal |
|||
b) |
Position/status |
Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044
|
|||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2022 to 30 September 2022.
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$31.02 |
448.172 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2022-09-23 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Dr Hal Dietz |
|||
b) |
Position/status |
Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044
|
|||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2022 to 30 September 2022.
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$31.02 |
529.657 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2022-09-23 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Dr Laurie Glimcher |
|||
b) |
Position/status |
Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044
|
|||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2022 to 30 September 2022.
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$31.02 |
1,684.039 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2022-09-23 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Dr Jesse Goodman |
|||
b) |
Position/status |
Independent Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W2044
|
|||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2022 to 30 September 2022.
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$31.02 |
529.657 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2022-09-23 |
|||
f) |
Place of the transaction
|
N/A |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.